Esophageal Cancer: Role of Imaging in Primary Staging and Response Assessment Post Neoadjuvant Therapy

https://doi.org/10.1053/j.sult.2016.02.003Get rights and content

Advances in the early detection and treatment of esophageal cancer have meant improved survival rates for patients with esophageal cancer. Accurate pretreatment and post–neoadjuvant treatment staging of esophageal cancer is essential for assessing operability and determining the optimum treatment plan. This article reviews the multimodality imaging approach in the diagnosis, staging, and assessment of treatment response in esophageal cancer.

Introduction

Esophageal cancer is the eighth most common malignancy worldwide with 456,000 new cases diagnosed in 2012.1 Rates have risen by 65% in men and 14% in women since the mid 1970s. In the UK, the incidence rate is the second highest in Europe for men and the highest for women. Although it is a leading cause of mortality (sixth most fatal cancer globally), survival rates have been improving with now approximately 20% surviving at least 5 years after diagnosis for all stages of esophageal cancer.1

Precise pretreatment staging of esophageal cancer is essential to determine which patients are suitable for surgery and to help formulate the optimal treatment plan. This minimizes inappropriate treatment and results in better clinical outcome. Computed tomography (CT), endoscopic ultrasound (EUS), and positron emission tomography-computed tomography (PET-CT) are all considered complementary modalities in the preoperative staging and therapeutic monitoring of esophageal cancer. This article reviews their clinical utility and relative strengths and weaknesses.

Section snippets

Histologic Types of Esophageal Cancer

More than 90% of esophageal cancers are either squamous cell carcinomas (SCCs) or adenocarcinomas. SCCs are linked to tobacco and alcohol abuse, whereas adenocarcinomas are highly associated with obesity and gastroesophageal reflux disease. SCC has historically been more prevalent than adenocarcinoma. However, over the last few decades, there has been an unexplained shift in histologic type and primary tumor location with a dramatic rise in rates of adenocarcinoma in the United States and

TNM Staging of Esophageal Cancer

Accurate staging of esophageal cancer requires an innate understanding of the pattern of tumor spread. Radiologists need to be familiar with the seventh edition of the TNM staging system (Table 1) as developed by American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC).7 This has made significant changes to the sixth edition with new definitions for the anatomical classifications of Tis, T4, N (regional lymph node), and M (distant metastasis) together with

Treatment of Esophageal Cancer

In the absence of metastatic disease, localized tumors (T1 and T2) have a high likelihood of R0 resection. In patients with stage I disease, especially Tis and T1aN0, endoscopic mucosal resection or endoscopic submucosal dissection can be considered, where local expertise is available. Primary oesophagectomy can be performed in patients with T1b (and any N) disease. For patients with T2 and T3 disease, trimodality treatment is now recommended, if tolerated, which involves neoadjuvant

T Staging

The CT provides the primary noninvasive method for staging esophageal cancer. Water (eg, 750 mL) can be given orally just before the CT scan to distend the esophagus, although the volume ingested may be limited by dysphagia. A distended esophagus has a normal wall thickness of 3 mm. Greater than 5 mm is considered abnormal. The CT defines the site of primary tumor. The esophagus is divided into the following 4 regions for purpose of classification and staging: cervical, upper thoracic,

Role of Imaging in the Assessment of Therapeutic Response

Neoadjuvant chemoradiotherapy is becoming more routinely used in patients with stage IIB and stage III disease. The aim is to treat coexistent micrometastases and downsize the primary tumor. Patients who demonstrate a major histopathological response (regression to less than 10% of the primary tumor) after preoperative treatment show improved survival. On current treatment regimes, 40%-50% of patients show a major histopathological response. The remaining cohort does not benefit from this

Interpretative Pitfalls in Assessing Treatment Response With PET-CT

The CT acquisition is performed with the patient in suspended expiration, whereas the PET images are acquired in quiet breathing. This results in slight misregistration of the fused PET-CT images and therefore discrepancies in the calculation of the SUVmax. This is most problematic at the level of the diaphragm where SUVmax can vary by up to 30%-50%.68 Hence, changes in SUVmax between baseline and follow-up PET-CT post neoadjuvant treatment in distal esophageal or gastroesophageal cancers in

Conclusions

The CT, EUS, and PET-CT all have important contributions in the initial staging and restaging post neoadjuvant treatment in patients with esophageal cancer.

The CT is required for the initial staging following confirmed histologic diagnosis of malignancy. The MDCT benefits from use of thin slices and multiplanar reformats. The EUS is the best test for assessing depth of tumor invasion and regional nodal involvement. The PET-CT is helpful for assessing distant metastatic disease but is of limited

References (69)

  • K.S. Parmar et al.

    Clinical impact of EUS guided FNA of celiac axis lymph nodes (M1a disease) in esophageal cancer

    Ann Thorac Surg

    (2002)
  • G.S. Cheung

    Contribution of PET-CT in radiotherapy planning of esophageal carcinoma: A review

    Radiography

    (2013)
  • H.W. Yeung et al.

    FDG-PET in esophageal cancer. Incremental value over computed tomography

    Clin Positron Imaging

    (1999)
  • H.M. Salahudeen et al.

    Impact of the introduction of integrated PET-CT in the preoperative staging pathway of patients with potentially operable esophageal carcinoma

    Clin Radiol

    (2008)
  • A.H. Hölscher et al.

    Prognostic impact of neoadjuvant chemoradiation in cT3 esophageal cancer—A propensity score matched analysis

    Eur J Cancer

    (2014)
  • R.J. Cerfolio et al.

    The accuracy of EUS with FNA, integrated PET with CT and CT in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy

    J Thorac cardiovasc Surg

    (2005)
  • S.G. Swisher et al.

    Utility of PET, CT and EUS to identify pathologic responders in esophageal cancer

    Ann Thoracic Surg

    (2004)
  • J. Willis et al.

    Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma

    Gastrointest Endosc

    (2002)
  • N.K. Cheedella et al.

    Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: Analysis in a large cohort

    Ann Oncol

    (2013)
  • J.J. Erasmus et al.

    Preoperative chemoradiation-induced ulceration in patients with esophageal cancer: A confounding factor in tumor response assessment in integrated CT-PET imaging

    J Thorac Oncol

    (2006)
  • World cancer research fund international and Cancer Research UK. Available at:...
  • J. Lagergren et al.

    Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma

    N Engl J Med

    (1999)
  • L.M. Brown et al.

    Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age

    J Natl Cancer Inst

    (2008)
  • W.J. Blot et al.

    The changing epidemiology of esophageal cancer

    Semin Oncol

    (1999)
  • A. Schmassmann et al.

    Changing incidence of gastric and oesophageal cancer subtypes in central Switzerland between 1982 and 2007

    Eur J Epidemiol

    (2009)
  • J.R. Siewart et al.

    Histologic tumor type is an independent prognostic parameter in oesophageal cancer. Lesson from more than 1000 consecutive resections at a single center in the western world

    Ann Surg

    (2001)
  • S.J. Hong et al.

    New TNM staging system for esophageal cancer: What chest radiologists need to know

    Radiographics

    (2014)
  • S.R. DeMeester

    Adenocarcinoma of the esophagus and cardia: A review of the disease and its treatment

    Ann Surg Oncol

    (2006)
  • L.E. Quint et al.

    Incidence and distribution of distant metastases from newly diagnosed esophageal cancer

    Cancer

    (1995)
  • Medical research council esophageal cancer working group

    Surgical resection with or without preoperative chemotherapy in esophageal cancer. A randomised controlled trial

    Lancet

    (2002)
  • D. Cunningham et al.

    MAGIC trail participants. Perioperative chemotherapy versus surgery along for resectable gastroesophageal cancer

    N Engl J Med

    (2006)
  • J.R. Siewert et al.

    Carcinoma of the cardia: Carcinoma of the gastroesophageal junction—classification, pathology and extent of resection

    Dis Esophagus

    (1996)
  • D. Picus et al.

    CT in the staging of esophageal carcinoma

    Radiology

    (1983)
  • M.S. Levine et al.

    Carcinoma of the esophagus

  • Cited by (0)

    View full text